Project

INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA

Ongoing - recruitment closed · 2022 until 2025

Fehr Martin, Bürki Ramona, Frehner Jan